Rimac Technology is the first to deploy NXP's S32E2 real-time processor series in its upcoming next-generation ECU platform for software-defined vehicles (SDV)NXP and Rimac's jointly developed centralized architecture consolidates more than 20 electronic control units into just three centralized unitsCollaboration enables OEMs to adopt SDV architectures with advanced domain and zonal control applications EINDHOVEN, The Netherlands, June 12, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ:NXPI), the worldwide leader in automotive processing, today announced its collaboration with Rimac Technology, a leading automotive industry supplier specialized in high-performance control sys

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated ap

Westlake Corporation (NYSE:WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake's composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materials for reuse in new or emerging applications aims to establish a more sustainable alternative to traditional disposal methods such as landfilling and incineration. Alpha Recyclage Composites, a fami

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces updated long term data (up to approximately three years of follow up) from the FELIX study of obecabtagen

Morgan Stanley upgraded LG Display from Underweight to Equal-Weight

Itau BBA upgraded Southern Copper from Underperform to Market Perform

BTIG Research reiterated coverage of Wingstop with a rating of Buy and set a new price target of $430.00 from $350.00 previously

RBC Capital Mkts reiterated coverage of Starbucks with a rating of Outperform and set a new price target of $100.00 from $95.00 previously

4 - ARDELYX, INC. (0001437402) (Issuer)

4 - New Horizon Aircraft Ltd. (0001930021) (Issuer)

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

4 - IRIDEX CORP (0001006045) (Issuer)

4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

4 - MP Materials Corp. / DE (0001801368) (Issuer)

4 - Unity Software Inc. (0001810806) (Issuer)

4 - ARDELYX, INC. (0001437402) (Issuer)

SCHEDULE 13D/A - Samsara Inc. (0001642896) (Subject)

144 - LiveWire Group, Inc. (0001898795) (Subject)

144 - LiveWire Group, Inc. (0001898795) (Subject)

SCHEDULE 13D/A - Ernexa Therapeutics Inc. (0000748592) (Subject)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

ST. LOUIS, June 11, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE:SF) today announced that Victor Nesi, Co-President and Head of the Institutional Group, will retire from his day-to-day operating responsibilities effective July 1, 2025, after 16 years of distinguished service. Mr. Nesi will, however, continue to serve the firm, simultaneously joining its Board of Directors. "Victor has been instrumental in building the platform we have today," said Ronald J. Kruszewski, Chairman and CEO of Stifel. "The transformation of our Institutional Group under his guidance is one of the great success stories in our firm's history. His strategic vision, leadership, and relentless focus on cli

Expands Board back to seven members Helios Technologies, Inc. (NYSE:HLIO) ("Helios" or the "Company"), a global leader in highly engineered motion control and electronic control technologies, today announced that its Board of Directors (the "Board") has appointed Ian Walsh to serve as director, effective June 5, 2025. He will serve as a member of the class of directors whose term will expire at the 2026 Annual Meeting of Shareholders. The Board also appointed Mr. Walsh to serve on the Board's Audit Committee and Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250611101051/en/Mr. Ian Walsh brings 35 years o

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.

    TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua

The shelf prospectus supplement, the corresponding base shelf prospectus and any amendment to the documents is accessible through SEDAR+ CALGARY, AB, June 11, 2025 /PRNewswire/ - Canadian Pacific Kansas City Limited (TSX:CP) (NYSE:CP) ("CPKC") announces that its wholly- owned subsidiary, Canadian Pacific Railway Company ("CPRC"), is issuing C$500 million of 4.00% Notes due 2032, C$600 million of 4.40% Notes due 2036 and C$300 million of 4.80% Notes due 2055, which will be guaranteed by CPKC (the "Offering"). The transaction is expected to close on June 13, 2025, subject to the satisfaction of customary closing conditions. The net proceeds from this Offering will be used to refinance CPRC's o

ORINDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (NASDAQ:MKZR) ("MacKenzie" or the "Company") is pleased to announce the successful refinancing of the Main Street West property in Napa, CA. The refinancing was completed with EverTrust Bank for approximately $9.5 million, a term for 3 years with a current interest rate of 7.5% (Prime).   The Main Street West property is 40,000 square feet with retail and professional suites located at 1250 Main Street in downtown Napa. Robert Dixon, CEO and President of MacKenzie Realty Capital, said, "Despite many challenges in the current commercial real estate financing market, we continue to see lender appetite for well-

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Equinox Gold Corp. (TSX:EQX) (NYSE:EQX) ("Equinox Gold" or the "Company") is updating its 2025 production and cost guidance to reflect the business combination with Calibre Mining Corp. ("Calibre"), which is expected to close around the end of June 2025, and the slower-than-planned ramp-up at the Company's Greenstone Gold Mine ("Greenstone") in Ontario, Canada. The Company expects pro forma full-year 2025 production of 785,000 to 915,000 ounces of gold, with total cash costs ("TCC") of $1,400 to $1,500 per ounce and all-in sustaining costs ("AISC") of $1,800 to $1,900 per ounce, including Calibre's full-year guidance (see Calibr

VANCOUVER, BC, June 11, 2025 /PRNewswire/ - West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX and NYSE:WFG) has declared a quarterly dividend of US$0.32 per share on the Common shares and Class B Common shares in the capital of the Company, payable on July 14, 2025 to shareholders of record on June 26, 2025. Dividends are designated to be eligible dividends pursuant to subsection 89(14) of the Income Tax Act (Canada) and any applicable provincial legislation pertaining to eligible dividends. Dividends are declared and payable in U.S. dollars. Shareholders may elect to receive their dividends in Canadian dollars. Details regarding the election procedure are available on our w

SC 13D/A - ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) (Subject)

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan